Midatech Pharma PLC Announces Closing of Offering, Revised Terms, AIM & Webinar

December 19, 2022 2:30 AM

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFERS OR SALES WOULD BE PROHIBITED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL OR A SOLICITATION TO BUY SECURITIES IN ANY JURISDICTION, INCLUDING THE UNITED STATES, CANADA, AUSTRALIA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA. NEITHER...

Read more

Edesa Biotech Reports Fiscal Year 2022 Results

December 16, 2022 9:00 AM

TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2022 and provided an update on its business.During the fiscal year, Edesa reported positive final results from the Phase 2 part of a Phase 2/3 study of its monoclonal antibody in Covid-19 patients...

Read more

Zentek Announces Successful Phase 2 Results of HVAC Testing

December 15, 2022 8:00 AM

GUELPH, ON / ACCESSWIRE / December 15, 2022 / Zentek Ltd. ("Zentek" or the "Company") (NASDAQ:ZTEK)(TSX-V:ZEN), an intellectual property development and commercialization company, reports, further to its press release of April 11, 2022, the successful completion of Phase 2 HVAC filter testing by the National Research Council of Canada ("NRC").The Company has received the preliminary report from Phase 2 testing under its Innovative Solutions...

Read more

Q2 Interim Report August-October 2022/2023

December 15, 2022 2:20 AM

UPPSALA, SE / ACCESSWIRE / December 15, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Successful capital acquisition paves the way for launch in the USASEK tQ2 22/23Q2 21/22May-Oct 22/23May-Oct 21/22Full year 21/22Net sales9612681,5066492,045Operating profit (loss)-23,310-14,314-43,973-26,552-60,101Profit (loss) for the period-23,250-14,388-44,254-26,613-60,003Earnings per share, after...

Read more

Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis

December 14, 2022 9:20 AM

NEW YORK, NY / ACCESSWIRE / December 14, 2022 / Qrons Inc. (OTCQB:QRON) announced today that it formed a collaboration with scientists at one of the largest public research universities in Israel, by which Tellurium based compounds in combination with Qrons' QS200™ product candidate and other configurations will be experimented as treatment for diffused axonal injuries (also commonly referred to as concussions) which accounts for...

Read more

Biovica Expects CLIA Certification During First Quarter 2023

December 13, 2022 4:10 PM

UPPSALA, SWEDEN / ACCESSWIRE / December 13, 2022 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) Biovica, active in cancer monitoring, today announces that the company expects to receive CLIA certification in during first quarter 2023.The Laboratory Field Services (LFS) of California Department of Public Health (CDPH) has informed Biovica that it has scheduled an on-site visit of Biovica's new laboratory in San Diego, California,...

Read more

A Sea Change in Sepsis Management from Horseshoe Crab Innovation

December 13, 2022 10:00 AM

GREENSBORO, NC / ACCESSWIRE / December 13, 2022 / Kepley Biosystems, a North Carolina biotechnology company, has been awarded a $1 million National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II grant to continue product development in sepsis diagnosis and management. The grant, entitled, "A Rapid, Sensitive Pathogen Typing and Antibiotic Sensitivity Test for Bloodstream Infections (COVID-19)" improves infectious...

Read more

Celcuity Closes $100 Million Private Placement

December 12, 2022 7:30 AM

MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proceeds of approximately $100 million, before deducting placement agent fees and other expenses. The closing follows dosage of the first patient in Celcuity's Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib, Celcuity's lead therapeutic...

Read more

Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium

December 9, 2022 8:40 AM

High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation statusMedian progression free survival (PFS) of 42.3 months was reported for patients who were treatment naïve in the advanced settingMINNEAPOLIS, MN / ACCESSWIRE / December 9, 2022 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology,...

Read more

Black Bird Biotech Secures Distribution Agreement for its MiteXstream Biopesticide

December 8, 2022 9:00 AM

FLOWER MOUND, TX / ACCESSWIRE / December 8, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, today announced that it has entered into a distribution agreement for its MiteXstreamTM biopesticide with Green Search, Inc., a Kingston, Ontario-based distributor of unique crop cultivation solutions, with operations in the U.S., Canada, The Netherlands and Brazil."We are extremely...

Read more

BioInvent Outlines Strong Progress in Clinical and Preclinical Pipeline at R&D Day 2022

December 8, 2022 7:55 AM

Current data on BI-1206 show three complete responses (two responses beyond two years) and four partial responses. Full approval received for starting subcutaneous administration.Recruitment in single agent and combo arms of BI-1808 Phase 1/2a trial progressing well.Dose escalation of BI-1607 progressing well with the first dose cohort completed.Results from Part A of BT-001 Phase 1/2a trial to be presented H1 2023E.LUND, SWEDEN / ACCESSWIRE /...

Read more

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering

December 7, 2022 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / December 7, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ: ENSC),(OTC PINK: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the pricing of an underwritten public offering of 2,900,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to...

Read more

Black Bird Biotech Secures Full-Page Print Package for 2023 in Nationally Distributed Cannabis Now Magazine

December 6, 2022 10:30 AM

FLOWER MOUND, TX / ACCESSWIRE / December 6, 2022 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, today announced that it has secured full-page ad space for its MiteXstreamTM biopesticide in all 2023 issues of the nationally distributed bi-monthly Cannabis Now Magazine, a leading publication serving the Cannabis Industry with an established social community exceeding 4.2 million....

Read more

Moon Surgical receives first FDA 510(k) clearance for its Maestro(TM) Surgical Robotics System

December 6, 2022 8:00 AM

The company's unique Maestro System is designed to augment the surgeon at the bedside in minimally invasive soft tissue surgical proceduresPARIS and SAN FRANCISCO / ACCESSWIRE / December 6, 2022 / Moon Surgical, a French-American pioneer in accessible surgical innovation, announced today the United States Food and Drug Administration (FDA) clearance for its unique Maestro surgical robotics system."At Moon Surgical, we are creating a new category...

Read more

Aqualung Therapeutics, an Immunotherapeutics Biotech Company, Receives First $1.5M Toward Series A Preferred Capital Raise; Will Present at 2023 Annual Biotech Showcase

December 5, 2022 10:40 AM

-Aqualung will present at the annual Biotech Showcase conference in San Francisco on January 10, 2023.-JSR Lifesciences invested $1.5M toward the preferred series A capital raise, October 2022.-The dosing of the P1A Healthy Human Volunteer Study with ALT-100 mAb is nearing completion, with no reported SAEs to date. Study to conclude by Q2 2023.TUCSON, AZ / ACCESSWIRE / December 5, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics...

Read more

Hexaell Announces NMPA (National Medical Products Administration, China) Clearance of Investigational New Drug (IND) Application for HepaCure Biocolumn, a Bioartificial Liver using Novel Cell Transdifferentiation Technology for the Treatment of Acute Liver Failure

December 5, 2022 9:20 AM

-Hexaell will initiate a Phase 1/2 clinical trial in the second half of 2023--HepaCure Biocolumn is the world first device-drug combination product based on cell transdifferentiation technology for treatment of acute-on-chronic liver failure.SHANGHAI, CHINA / ACCESSWIRE / December 5, 2022 / Hexaell Biotech Co., Ltd announced that the China National Medical Products Administration (NMPA, formerly CFDA) has cleared the IND, enabling the company to...

Read more

emyria to present at the "Planet MicroCap Showcase: VIRTUAL 2022" Wednesday, December 7, 2022

December 4, 2022 11:00 AM

PERTH, AUSTRALIA / ACCESSWIRE / December 4, 2022 / emyria, (ASX:EMD) a clinical-stage biotech accelerating treatment development for unmet medical needs, today announced that it will be presenting at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022, at 4:00 pm EST.Managing Director and CEO of Emyria, Dr Michael Winlo, will be hosting the presentation and answering questions at the conclusion.To access the live...

Read more

Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference

December 2, 2022 8:00 AM

TORONTO, ON / ACCESSWIRE / December 2, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, will participate in a panel discussion and host one-on-one meetings at the Cantor Fitzgerald Medical Dermatology, Opthalmology & Medtech Conference.The panel discussion is scheduled to take place on...

Read more

Biovica Establishes Experienced US Sales Team

December 1, 2022 8:50 AM

UPPSALA, SE / ACCESSWIRE / December 1, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces that the company has employed a sales team of total of eight people to secure a fast and smooth launch and the further commercial development of DiviTum® TKa on the US market.Biovica's US organization is growing in preparation to the upcoming launch of the blood-based test...

Read more

Enzolytics Recognizes World AIDS Day and Highlights the Company's Focus on Producing Effective Therapies for Treating HIV

December 1, 2022 6:00 AM

COLLEGE STATION, TX / ACCESSWIRE / December 1, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).World AIDS Day has been recognized on this day since 1988. It is an important day for the world to reflect on those who have been lost in the HIV pandemic and recommit to the challenge necessary to address this deadly disease.But why has the world failed to conquer HIV?Even though there are treatments for those with HIV -...

Read more